25 research outputs found
Life cycle and precopulatory mate guarding of <i>Goidelia japonica</i> (Copepoda: Poecilostomatoida: Echiurophilidae) associated with the echiuran <i>Urechis unicinctus</i>
Cluster III nifH-harboring microbes dominated diazotroph communities in the Chukchi Sea (western Arctic Ocean)
Cluster III (putative anaerobic bacteria) dominate the diazotroph community in the Chukchi Sea, Pacific sector of the Arctic Ocean
Datasets of the paper entitled "Assimilation and oxidation of urea-derived nitrogen in the summer Arctic Ocean"
Nitrification and its influence on biogeochemical cycles from the equatorial Pacific to the Arctic Ocean
Which patients benefit from the inhibition of renin-angiotensin system in advanced pancreatic cancer? An exploratory analysis in 349 patients.
Effect of non-anticancer drugs on prognosis of pancreatic cancer (PaC) receiving chemotherapy.
Additional file 2 of Genomic and metagenomic analysis of microbes in a soil environment affected by the 2011 Great East Japan Earthquake tsunami
Relative abundance of functional gene categories in the Arthrobacter genomes. The relative abundance of CDSs assigned to each eggNOG functional category is plotted for each Arthrobacter genome. (PDF 166 kb
A phase 1 trial of GSL (gemcitabine, S-1, LV) combination therapy in advanced pancreatic cancer.
Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers
Gemcitabine chemotherapy has been the standard for advanced pancreatic cancer for more than a decade. New oral fluoropyrimidines such as S-1 and capecitabine are other key drugs. Gemcitabine plus erlotinib was the only combination therapy that significantly prolonged survival, although the effect was minimal. Little or no improvement in survival with recent molecular-targeted drugs might be attributed to the very high incidence of K-ras gene mutation in pancreatic cancer. Recently, the non-gemcitabine-based-regimen of FOLFIRINOX showed significantly greater overall survival compared with gemcitabine for the first time. For biliary tract cancer, gemcitabine plus cisplatin combination chemotherapy has been proved to significantly prolong survival and will become the standard therapy. Further improvement in survival is expected by the addition of cetuximab